LLS Launches Co-Pay Assistance Fund for Mantle Cell Lymphoma
The Leukemia and Lymphoma Society, the largest charity in the world dedicated to blood disorders, has announced a new co-pay assistance program fund.
The Leukemia and Lymphoma Society's Co-Pay Assistance Program provides direct financial assistance to patients living with a blood cancer to help them pay for insurance premiums and co-pay obligations.
A new assistance program
The latest disease Co-Pay Assistance Program fund at the LLS has been established for qualified patients who have been diagnosed with mantle cell lymphoma (MCL).
The MCL co-pay program is available for patients who have health insurance, including Medicare and Medicaid, and who meet specific financial criteria.
Approved MCL patients might receive as much as $5,000 per year. Acceptance is provided on a first-come, first-served basis. It remains open for as long as funding is available.
Patients can apply for the program by calling toll-free (877) 557-2672 or by going online to www.lls.org/copay.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
